Biotech News

Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

Aprea Therapeutics (APRE)Aprea TherapeuticsConference / presentation

DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced

Related news

APREAprea Therapeutics2026-11-20 14:00 EST

Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona

APREAprea Therapeutics2026-11-04 13:30 EST

Aprea Therapeutics Announces Third Quarter 2026 Financial Results

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

CGEMCullinan Therapeutics, Inc.2026-11-04 14:14 EST

Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

MMSIMerit Medical2026-11-05 14:25 EST

Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

Aprea Therapeutics

DNA Damage Response Oncology Aprea Therapeutics develops precision medicines that exploit vulnerabilities in cancer-cell DNA replication and repair. Its programs target biomarker-defined tumors while seeking to limit effects on healthy cells. APR-1051 APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for...

Recent company news

Stock data

Close
0.49 USD
Market cap
9.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States